Financing - March 9, 2015
Lundbeck Increases Share Capital
H. Lundbeck A/S has decided to increase its share capital by DKK 202,400, as a result of the exercise of employee warrants. The increase is affected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: […]
Financing - March 9, 2015
Novo’s IT Shares on the Rise
On its first day on the Copenhagen stock market Friday, Novo Nordisk’s newly public IT business got off to a fast start, with shares rising by as much as 44 percent, according to Reuters. Investors quickly bid up shares in NNIT, which had an offering price of 125 Danish kroner, or about $18—a figure analysts […]
Financing - December 16, 2014
BenGenBio Raises NOK90 Million
BerGenBio AS, a Norwegian biopharmaceutical company focused on developing medications for aggressive drug- resistant cancers, announced that it has raised NOK90 million (c. $15 million) in a private placing from new and existing investors. BerGenBio will use the proceeds from the financing to support the development of its pipeline of innovative cancer therapeutics, in particular an enlarged […]
Financing - October 29, 2014
Pfizer buys back billions in stock
Pfizer is to continue buying back stock, with the board authorizing a new $11 billion share repurchase plan, deflating expectations that it will make a new bid for AstraZeneca. Shares in AstraZeneca fell 1.2 percent by 0800 GMT on Friday following the news. Pfizer is in the middle of a strategic transformation, and has split […]
Financing - October 16, 2014
Forward Pharma prices IPO of ADSs
Danish Forward Pharma A/S has announced the pricing of its initial public offering of 10,500,000 American Depositary Shares, ADSs. The ADSs represent the biopharmaceutical’s ordinary shares at a price to the public of USD 21.00 per ADS. The share were expected to begin trading on October 15 on the NASDAQ Global Select Market under the ticker […]
Financing - September 29, 2014
Nanovi secures EUR 2.7 million to market BioXmark
Nanovi, specialized in the development of advanced biomaterials for use in the radiotherapy of cancer, has secured EUR 2.7M from current investors to bring BioXmark technology to the market. BioXmark is a novel injectable liquid tissue marker which improves the accuracy and quality of radiation therapy and will be available for commercial use in Europe during the […]
